Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156826 | 1.00 | RAB9A (0.46) | RAB9ASMN1; SMN2GFERLMNAHTT | |
| SCHEMBL21156828 | 0.90 | DYRK1A (0.59) | RAB9ASMN1; SMN2GFERLMNAHTT | |
| SCHEMBL30593442 | 0.90 | DYRK1A (0.59) | RAB9ASMN1; SMN2GFERLMNAHTT | |
| SCHEMBL21156832 | 0.82 | QPCT (0.53) | DYRK1A | |
| SCHEMBL21156277 | 0.80 | DYRK1A (0.56) | DYRK1A | |
| SCHEMBL21156829 | 0.77 | DYRK1A (0.59) | SMN1; SMN2LMNADYRK1ATP53MAPT | |
| SCHEMBL30593440 | 0.76 | DYRK1A (0.59) | SMN1; SMN2LMNADYRK1ATP53USP2 | |
| SCHEMBL21156830 | 0.76 | DYRK1A (0.59) | SMN1; SMN2LMNADYRK1ATP53USP2 | |
| SCHEMBL21155869 | 0.72 | DYRK1A (0.47) | DYRK1A | |
| SCHEMBL21156833 | 0.72 | DYRK1A (0.56) | SMN1; SMN2GFERHTTDYRK1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-05-30 | — | — | US | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, DYRK1A, GLP1R | RAB9A 1873/4885SMN1; SMN2 1981/4885GFER 3751/4885 |
| US-12630803-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | GLP1R, DYRK1A, DYRK1B | RAB9A 2006/4885SMN1; SMN2 1053/4885GFER 3417/4885 |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | IAPP, GLP1R, GPR119 | RAB9A 1963/4885SMN1; SMN2 1878/4885GFER 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.